REFERENCES

1. Snijders RJM, Holzgreve W, Cuckle H, Nicolaides KH. Maternal age-specific risks for trisomies at 9-14 weeks gestation. Prental Diagn 1994;14:543-52.

2. Nicolaides KH. Screening for fetal aneuplodies at 11 to 13 weeks.

3. Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal Diagn Ther 2014;35:156-73.

4. National Institute for Health and Clinical Excellence (NICE). Antenatal care for uncomplicated pregnancies. Clinical guideline [CG62], updated 2019. London: NICE; 2008.

5. Royal College ofObstetricians and Gynaecologists (RCOG). Routine Ultrasound Screening in Pregnancy: Protocol, Standards and Training. Report of the RCOG Working Party. London: RCOG; 2000.

6. Rosendahl H, Kivinen S, Antenatal detection of congenital malformations by routine ultrasonography. Obstet Gynaecol 1989;73:947-59.

7. Saari-Kemppainen A, Karajalainen O, Ylostalo P. Ultrasound screening and prenatal mortality: controlled trial of systematic one- stage screening in pregnancy. The Helsinki ultrasound trial. Lancet 1990;336:387-91.

8. Shirley IM, Bottomley F, Robinson VP. Routine radiographer screening for fetal abnormalities in unselected population. Br J Radiol 1992;65:564-69.

9. Ewigman BG, Crane JP, Frigoletto FD, et al. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group. N Eng J Med 1993;329:821-27.

10. Eidem I, Stene LC, Henriksen T, et al. Congenital anomalies in newborns of women with type 1 diabetes: nationwide population­based study in Norway, 1999-2004. Acta Obstet Gynecol Scand 2010;89:1403-11.

11. Rosa F. Spina bifida in infants of women treated with carbamaze­pine during pregnancy. N Engl J Med 1991;324:674-77.

12. Jouannic JM, Thieulin AC, Bonnet D, et al. Measurement of nuchal translucency for prenatal screening of congenital heart defects: a population-based evaluation.

13. Collins JS, Canfield MA, Pearson K, et al. Public health projects for preventing the recurrence of neural tube defects in the United States. Birth Defects Res A Clin Mol Teratol 2009;85:935-38.

14. Snijders RJM, Sundberg K, Holzgreve W, et al. Maternal age and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999;13:167-70.

15. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down’s syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-67.

16. Wald NJ, Rodeck C, Hackshaw AK, et al. SURUSS Research group. First and second trimester antenatal screening for Down’s syn­drome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1-88

17. Snijders RJ, Noble P, Sebire N, et al. Fetal Medicine Foundation First Trimester Screening Group. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998;352:343-46.

18. Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translu­cency: ultrasound screening for chromosomal defects in first tri­mester of pregnancy. Br Med J 1992;304:867-89.

19. Souka AP, Von Kaisenberg CS, Hyett JA, et al. Increased nu­chal translucency with normal karyotype. Am J Obstet Gynecol 2005;192:1005-1021.

20. Nicolaides KH, Snijders RJM, Gosden RJM, et al. Ultrasono­graphically detectable markers of fetal chromosomal abnormal­ities. Lancet 1992;340:704-707.

21. Wright D, Kagan KO, Molina FS, et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376-83.

22. Spencer K, Souter V, Tul N, et al. A screening program for trisomy 21 at 10- 14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasmaprotein-A. Ultrasound Obstet Gynecol 1999;13:231-37.

23. Cicero S, Curcio P, Papageorghiou A, et al. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observa­tional study. Lancet 2001;358:1665-67.

24. Maiz N, Wright D, Ferreira AF, et al. A mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11-13 weeks’ gestation. FetalDiagn Ther 2012;31:221-29.

25. Kagan KO, Valencia C, Livanos P, et al. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 2009;33:18-22.

26. Nicolaides KH. Ultrasound Markers for Fetal Chromosomal Defects. Carnforth: Parthenon Publishing; 1996.

27. Agathokleous M, Chaveeva P, Poon LCY, et al. Meta-analysis of second-t rimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013;41:247-61.

28. Royal College of Obstetricians and Gynaecologists (RCOG). Amniocentesis and Chorionic Villus Sampling. Green-top Guideline No. 8. London: RCOG; 2010.

29. Wijnberger LD, van der Schouw YT, Christiaens GC. Learning in medicine: chorionic villus sampling. Prenat Diagn 2000;20:241-46.

30. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-ana- lysis. Ultrasound Obstet Gynecol 2015;45:16-26.

31. International Society of Ultrasound in Obstetrics & Gynecology Education Committee. Sonographic examination of the fetal cen­tral nervous system: guidelines for performing the ‘basic exam­ination’ and the ‘fetal neurosonogram’ Ultrasound Obstet Gynecol 2007;29:109-16.

32. Pilu G, Nicolaides KH. Diagnosis of Fetal Abnormalities— The 18­23 Week Scan. Carnforth: The Parthenon Publishing Group; 1994.

33. Sohn YS, Kim MJ, Kwon JY, Kim YH, Park YW The usefulness of fetal MRI for prenatal diagnosis Yonsei Med J 2007;48:671-77.

34. Boyd P, DeVigan C, Khoshnood B, et al. Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and ter­mination rates for neural tube defects and Down’s syndrome. BJOG 2008;115:689-96.

35. Garne E, Loane M, Dolk H, et al. Prenatal diagnosis of severe structural congenital malformations in Europe. Ultrasound Obstet Gynecol 2003;22:555-58.